Barclays’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-18,800
| Closed | -$211K | – | 7343 |
|
|
2017
Q3 | $211K | Sell |
18,800
-100
| -0.5% | -$1.1K | ﹤0.01% | 4384 |
|
|
2017
Q2 | $208K | Buy |
18,900
+16,700
| +759% | +$167K | ﹤0.01% | 4324 |
|
|
2017
Q1 | $22K | Sell |
2,200
-11,800
| -84% | -$118K | ﹤0.01% | 5777 |
|
|
2016
Q4 | $151K | Hold |
14,000
| – | – | ﹤0.01% | 4442 |
|
|
2016
Q3 | $144K | Buy |
+14,000
| New | +$152K | ﹤0.01% | 4238 |
|
|
2015
Q4 | – | Sell |
-500
| Closed | -$3K | – | 6999 |
|
|
2015
Q3 | $3K | Sell |
500
-3,000
| -86% | -$25.7K | ﹤0.01% | 6272 |
|
|
2015
Q2 | $32K | Buy |
3,500
+500
| +17% | +$4.55K | ﹤0.01% | 5424 |
|
|
2015
Q1 | $24K | Buy |
+3,000
| New | +$23.9K | ﹤0.01% | 5743 |
|
|
2014
Q4 | – | Sell |
-1,500
| Closed | -$9K | – | 7804 |
|
|
2014
Q3 | $9K | Buy |
1,500
+1,000
| +200% | +$5.99K | ﹤0.01% | 6966 |
|
|
2014
Q2 | $3K | Buy |
+500
| New | +$2.43K | ﹤0.01% | 7346 |
|
|
2013
Q4 | – | Sell |
-1,000
| Closed | -$5K | – | 7809 |
|
|
2013
Q3 | $5K | Sell |
1,000
-4,000
| -80% | -$22.3K | ﹤0.01% | 7007 |
|
|
2013
Q2 | $25K | Buy |
+5,000
| New | +$23.8K | ﹤0.01% | 6733 |
|
Barclays's SCLN Position: Q4 2017 in Review
Barclays sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 113,303 shares — an estimated $1.27M sold.
Barclays first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $1.53M in Q4 2016. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Barclays reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Barclays sold 113,303 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $1.27M.
- Barclays first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Barclays's Sciclone Pharmaceuticals Inc position peaked at $1.53M in Q4 2016.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Barclays's 13F filing for Q4 2017, filed 14 Feb 2018.